Serdemetan

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2013
012320112013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Serdemetan (JNJ-26854165), an antagonist to Mdm2, was anticipated to promote the activation of p53. While regulation of p53 by… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
JNJ-26854165 (serdemetan) has previously been reported to inhibit the function of the E3 ligase human double minute 2, and we… (More)
Is this relevant?
2013
2013
JNJ-26854165 (serdemetan) has previously been reported to inhibit the function of the E3 ligase human double minute 2, and we… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ… (More)
  • table I
  • table II
Is this relevant?
2011
2011
Serdemetan (JNJ-26854165) is a novel tryptamine compound with antiproliferative activity in various p53 wild-type (WT) tumor cell… (More)
Is this relevant?
2011
2011
PURPOSE Originally isolated on the basis of its ability to induce p53, serdemetan showed potent activity in various preclinical… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2011
2011
Purpose:Originally isolated on the basis of its ability to induce p53, serdemetan showed potent activity in various preclinical… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?